908240-50-6

Basic information

• Product Name: 2,4-Dichloropyrido[3,4-d]pyrimidine
• Synonyms: 2,4-dichloropyrido[3,4-d]pyrimidine
• CAS NO: 908240-50-6
• Molecular Formula: C₇H₃Cl₂N₃
• Molecular Weight: 200.02
• Product Categories: CHIRAL CHEMICALS
• Mol File: 908240-50-6.mol

Chemical Properties

• Boiling Point: 302.4±24.0 °C(Predicted)
• Appearance: /
• Density: 1.573
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.30±0.30(Predicted)
• CAS DataBase Reference: 2,4-Dichloropyrido[3,4-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloropyrido[3,4-d]pyrimidine(908240-50-6)
• EPA Substance Registry System: 2,4-Dichloropyrido[3,4-d]pyrimidine(908240-50-6)

Safety Data

• Hazardous Substances Data: 908240-50-6(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Industry:
2,4-Dichloropyrido[3,4-d]pyrimidine is used as a potential herbicide for controlling weeds in various crops. It has been evaluated for its effectiveness in this application, and its chemical properties and toxicological effects have been studied to assess its safety and environmental impact. The development of 2,4-Dichloropyrido[3,4-d]pyrimidine as a new herbicide could provide an additional tool for crop protection and contribute to more efficient and sustainable agricultural practices.

InChI:InChI=1/C7H3Cl2N3/c8-6-4-1-2-10-3-5(4)11-7(9)12-6/h1-3H

Upstream product

• 64188-97-2 3-aminopyridine-4-carboxamide 
• 21038-67-5 pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 

Downstream Products

• 1262866-87-4 C₃₁H₂₀N₄ 
• 1262866-86-3 C₁₃H₈ClN₃ 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY

The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides cell populations, preparations, uses and methods of therapy comprising said cells.

METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY

The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides a cell populations, preparations, uses and methods of therapy comprising said cells.

6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS

The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein (A1 and A2). The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

GLUCOSE UPTAKE INHIBITORS

Provided hererin are compounds that modulate glucose uptake activityand are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: Formula (I) wherein the variables have the values disclosed herein.

HISTONE DEMETHYLASE INHIBITORS

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

HISTONE DEMETHYLASE INHIBITORS

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like

7-AZA-QUINAZOLINE PDE10 INHIBITORS

The present invention is directed to 7-aza-quinazoline compounds of general structural formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10).

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase

We describe a novel series of potent inhibitors of the kinase activity of mTOR. The compounds display good selectivity relative to other PI3K-related kinase family members and, in cellular assays, inhibit both mTORC1 and mTORC2 complexes and exhibit good antiproliferative activity.